Invention Application
- Patent Title: AGENTS ENCODING CLDN6 AND CD3 BINDING ELEMENTS FOR TREATING CLDN6-POSITIVE CANCERS
-
Application No.: US18578844Application Date: 2022-07-13
-
Publication No.: US20250009780A1Publication Date: 2025-01-09
- Inventor: Ugur SAHIN , Christiane STADLER , Claudia LINDEMANN , Ursula ELLINGHAUS , Hayat BÄHR-MAHMUD , Leyla FISCHER , Anuhar CHATURVEDI , Gábor BOROS , Jonas REINHOLZ , Sergey BESSONOV , Katalin KARIKÓ
- Applicant: BIONTECH SE
- Applicant Address: DE Mainz
- Assignee: BIONTECH SE
- Current Assignee: BIONTECH SE
- Current Assignee Address: DE Mainz
- Priority: WOPCT/EP2021/069869 20210715
- International Application: PCT/EP2022/069659 WO 20220713
- Main IPC: A61K31/7115
- IPC: A61K31/7115 ; A61K9/00 ; A61K9/127 ; A61K9/51 ; A61K45/06 ; A61P35/00 ; C07K16/28
Abstract:
The present invention generally relates to binding agents that are at least bispecific for the binding to CD3 and CLDN6, i.e., they are capable of binding to at least CD3 and CLDN6. Specifically, the present invention relates to RNA encoding these binding agents which may be used in the treatment or prevention of cancer in a subject.
Information query
